Matches in DBpedia 2015-10 for { ?s ?p "Alain L. de Weck, (July 26, 1928 – April 8, 2013), was a Swiss immunologist and allergist. His main scientific contributions were in the area of characterization and prevention of drug allergy. He was the founding director of the Institute of Clinical Immunology at the University of Bern from 1971 to 1993 and authored or co-authored over 600 peer-reviewed publications. He is the recipient of a number of patents that led to commercial allergy products and services. He served as president of international scientific organizations such as the International Union of Immunological Societies (IUIS) and the International Association for Allergy and Clinical Immunology (IAACI) (now the World Allergy Organization) and was founder and later CEO of the Centre Médical des Grand-Places (CMG) company, acquired by Heska of Fort Collins (Nasdaq: HSKA) in 1997. In later years he continued his research at the University of Navarra in Spain and wrote on a wide range of topics such as the distinction between science and pseudo-science, the emergence of genetically modified organisms (GMOs) and comparative health care policy."@en }
Showing triples 1 to 1 of
1
with 100 triples per page.
- Alain_de_Weck abstract "Alain L. de Weck, (July 26, 1928 – April 8, 2013), was a Swiss immunologist and allergist. His main scientific contributions were in the area of characterization and prevention of drug allergy. He was the founding director of the Institute of Clinical Immunology at the University of Bern from 1971 to 1993 and authored or co-authored over 600 peer-reviewed publications. He is the recipient of a number of patents that led to commercial allergy products and services. He served as president of international scientific organizations such as the International Union of Immunological Societies (IUIS) and the International Association for Allergy and Clinical Immunology (IAACI) (now the World Allergy Organization) and was founder and later CEO of the Centre Médical des Grand-Places (CMG) company, acquired by Heska of Fort Collins (Nasdaq: HSKA) in 1997. In later years he continued his research at the University of Navarra in Spain and wrote on a wide range of topics such as the distinction between science and pseudo-science, the emergence of genetically modified organisms (GMOs) and comparative health care policy.".